Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial
European Urology Focus · 2025-11 · 11 (6) · 855-862
DOI: 10.1016/j.euf.2025.06.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Urology Focus, 2025-11. Verfasst von Lars Björnebo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: lars.bjornebo@ki.se. Hauptthemen laut MEDLINE: Early Detection of Cancer, Magnetic Resonance Imaging, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Karolinska Institutet, Cancerfonden.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Prostate cancer screening is challenged by overdetection, overtreatment, and high resource use. Prostate-specific antigen (PSA) density (PSAD) correlates more strongly with clinically significant cancer than PSA alone. We compare outcomes using various PSAD cutoffs to select men for magnetic resonance imaging (MRI). METHODS: STHLM3MRI is a screening-by-invitation trial with 49 118 men invited and 12 750 screened. In the experimental arm, participants with elevated PSA (≥3 ng/ml) had MRI and, if positive [PI-RADS] score ≥3), systematic and targeted biopsies. Evaluated PSAD cutoffs were 0.075, 0.10, 0.125, and 0.15 ng/ml2. Prostate volume was measured by MRI or transrectal ultrasound. The primary endpoint was Gleason ≥3 + 4 cancer detection. The secondary endpoints were Gleason 6 and ≥4 + 3 cancer detection, and the number of MRI scans and biopsies. Relative positive fractions (RPFs) compared the outcomes using PSA ≥3 ng/ml alone. KEY FINDINGS AND LIMITATIONS: Of 7609 men in the experimental arm, 929 (12.2%) had PSA ≥3 ng/ml, and 846 (91%) underwent MRI, with 38% having a PI-RADS score of ≥3. The median prostate volume was 45 ml (interquartile range [IQR], 33-62 ml) and PSAD 0.10 ng/ml2 (IQR, 0.07-0.14 ng/ml2). A PSAD cutoff of 0.075 ng/ml2 reduced Gleason 6 cancer detection by 17% (RPF, 0.83; 95% confidence interval [CI], 0.72-0.96), lowered MRI use by 28% (RPF, 0.72; 95% CI, 0.69-0.75), and missed 5% (RPF, 0.95; 95% CI, 0.92-0.98) of Gleason ≥3 + 4 cancer cases, with no difference in Gleason ≥4 + 3 cancer detection. Higher PSAD thresholds reduced Gleason 6 cancer detection and MRI use, but lowered Gleason ≥3 + 4 cancer detection. Limitations include assumed equivalency between MRI and ultrasound volume. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of PSAD before MRI lowers overdiagnosis and resource use, while maintaining detection of significant cancer cases. Our results suggest that a PSAD cutoff above 0.075 ng/ml2 is not advisable, regardless of age, due to the increased risk of missing cancer cases with Gleason scores ≥3 + 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: lars.bjornebo@ki.se.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Sciences at Danderyd Hospital, Danderyd, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Diagnostic Radiology, Karolinska Institutet, Stockholm, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Förderung
- Vetenskapsrådet
- Karolinska Institutet
- Cancerfonden
- Forskningsrådet för hälsa, arbetsliv och välfärd
- Åke Wiberg Stiftelse
Zitieren
APA
Björnebo, L., Discacciati, A., Abbadi, A., Falagario, U. G., Engel, J. C., Vigneswaran, H. T., Jäderling, F., Grönberg, H., Eklund, M., Lantz, A., & Nordström, T. (2025). Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial. European Urology Focus, 11(6), 855-862. https://doi.org/10.1016/j.euf.2025.06.008
Vancouver
Björnebo L, Discacciati A, Abbadi A, Falagario UG, Engel JC, Vigneswaran HT, et al. Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial. European Urology Focus. 2025;11(6):855-862. doi:10.1016/j.euf.2025.06.008
BibTeX
@article{Bjrnebo2025,
author = {Björnebo, Lars and Discacciati, Andrea and Abbadi, Ahmad and Falagario, Ugo Giovanni and Engel, Jan Chandra and Vigneswaran, Hari T and Jäderling, Fredrik and Grönberg, Henrik and Eklund, Martin and Lantz, Anna and Nordström, Tobias},
title = {Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial},
journal = {European Urology Focus},
year = {2025},
volume = {11},
number = {6},
pages = {855--862},
doi = {10.1016/j.euf.2025.06.008}
}
EUVIMED